ANTICANCER EFFECTS OF VITAMIN K COMBINED WITH TRANSARTERIAL CHEMOEMBOLIZATION IN HEPATOCELLULAR CARCINOMA; A PROSPECTIVE, RANDOMIZED TRIAL.
<div><p><b>Background: </b>We have previously reported that vitamin K dosing augments the anticancer effects of sorafenib by suppressing levels of des-γ-carboxy prothrombin (DCP), a known tumor growth and angiogenesis factor produced in HCC under sorafenib-induced ischemia. Herein, we aimed to establish whether vitamin K dosing could afford a similar anticancer effect when combined with transarterial chemoembolization (TACE), known to induce ischemic tumor necrosis in HCC.</p>